Us Bancorp \De\ Inhibrx, Inc. Transaction History

Us Bancorp \De\

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 09, 2024	BUY	$14.5 - $38.0 $4,393 - $11,514	303 Added 156.99%	496 $18,000
Q3 2023 Nov 03, 2023	BUY	$15.75 - $26.31 $2,016 - $3,367	128 Added 196.92%	193 $3,000
Q2 2023 Aug 09, 2023	BUY	$16.96 - $27.82 $1,102 - $1,808	65 New	65 $1,000
Q3 2022 Oct 27, 2022	SELL	$11.58 - $24.73 $220 - $469	-19 Reduced 13.38%	123 $2,000
Q2 2022 Aug 01, 2022	BUY	$8.52 - $25.26 $1,209 - $3,586	142 New	142 $2,000
Q1 2022 May 11, 2022	SELL	$19.89 - $43.18 $238 - $518	-12 Closed	0 $0
Q4 2021 Feb 11, 2022	BUY	$26.75 - $46.02 $321 - $552	12 New	12 $1,000

18.6K

Ticker INBX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,057,700
Market Cap $565M
Description
Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcin...

Get notified when there are updates to the investment portfolio of Us Bancorp \De\, based on Form 13F filings with the SEC.

Stay updated on Us Bancorp \De\ with notifications on news.